Study on Gilteritinib, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Exclusion Criteria

• Have acute promyelocytic leukemia (APL) or active central nervous system involvement with AML.
• Have a history of certain blood disorders or specific gene changes related to leukemia.
• Have been treated with CAR-T cell therapy for AML or MDS, except for certain allowed treatments like hydroxyurea or leukapheresis.
• Are receiving other experimental treatments or drugs that affect certain liver enzymes.
• Have consumed grapefruit, Seville oranges, or starfruit within 3 days before starting the study.
• Have severe heart conditions or a history of Long QT Syndrome.
• Have another cancer diagnosed within the last 2 years, with some exceptions.
• Have uncontrolled health issues like high blood pressure, infections, heart failure, or respiratory disease.
• Have gastrointestinal issues affecting drug absorption.
• Have active hepatitis B or C or other liver disorders.
• Have had major surgery within 4 weeks before starting the study.
• Have allergies to the study drugs.
• Have a recent positive COVID-19 test without a follow-up negative result.
• Require certain medications that interfere with the study drugs, except for specific antifungal treatments during the first phase.
• Do not have specific FLT3 gene mutations.